Macromolecular Modeling Blog ™

Please submit a resume and cover letter to hr@adimab.com.

Description

Adimab is looking for scientists with experience in computational protein design to join its Computational Biology group. Successful candidates will work on developing novel computational algorithms and software for rational structure-based design and optimization of antibody molecules and libraries. The computational effort will be closely linked to experimental sequence and binding information obtained from Adimab’s validated, high-throughput antibody discovery platform.

Qualifications

• Ph.D. in Biophysics, Biochemistry or related fields
• Previous academic or biotech industry experience in developing and employing protein design and/or docking algorithms and software
• Strong programming experience in C++ , C or Python
• Strong intuitive grasp of protein structure and function

About Adimab

Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

For more information, visit http://www.adimab.com.

Adimab is located in New Hampshire’s beautiful Upper Connecticut River Valley, just minutes from Dartmouth College, Dartmouth Medical School, the Tuck School of Business, the Thayer School of Engineering, and Dartmouth-Hitchcock Medical Center. Adimab offers individually tailored compensation packages that are comprised of competitive salary, bonus, and equity components in addition to a world class working environment in a newly constructed lab.

In a post yesterday on the Bleeding Edge Biotech Blog, Adam Kraut gives an expanded version of his article for Bio-IT World entitled Antibody Docking on the Amazon Cloud describing how Pfizer is leveraging the power and flexibility of cloud computing to run antibody docking simulations using Rosetta. Pfizer employed BioTeam (which Kraut consults for) to port Rosetta to the cloud. This is a fascinating article and certainly the Pfizer/BioTeam/Rosetta/Amazon synergy is a phenomenon on the bleeding edge.

I would add to the article that Jeffrey Gray at Johns Hopkins University was the lead developer of RosettaDock and RosettaAntibody. Rosetta has become synonymous with David Baker (and for good reason), but it is important to acknowledge continuing contributions to Rosetta outside of the Baker lab. Scientific collaborations can dissolve quickly when recognition is unevenly distributed, whether internally or as a result of outside perceptions (i.e. not as the result of any intentions by researchers in the collaboration).

If you use or write about Rosetta, please help us keep this unique collaboration going by acknowledging and citing the individual developers and researchers and their current labs!!!!

Carlos J. Camacho et al. study the relationship between peptide stabilities and their immunogenicity. They present a model system of several peptides corresponding to portions of murine HRS which are capable of inducing anti-protein antibodies of varying affinity and temporal persistence. On this system they show by molecular dynamics simulations, that sequences of the most immunogenic peptides correspond to highly ordered structural motifs in the parent protein. Competitive ELISAs provide direct evidence that these peptides share structural determinants with native protein. More interestingly they address the question of how can these less stable peptides induce the same immunogenic response. By Nir London

(more…)